Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
Sight Sciences Announces Surgical Glaucoma Investor Symposium On April 13, 2023, Sight Sciences, Inc. (Nasdaq: SGHT) revealed plans for a Surgical Glaucoma Investor Symposium on May 5, 2023, in San Diego, CA, at 6:00 pm PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sight Sciences Announces Surgical Glaucoma Investor Symposium
On April 13, 2023, Sight Sciences, Inc. (Nasdaq: SGHT) revealed plans for a Surgical Glaucoma Investor Symposium on May 5, 2023, in San Diego, CA, at 6:00 pm PT. The event will feature insights from leading glaucoma surgeons and remarks from the executive management team.
Attendance is limited and requires advance registration by April 21, 2023. A live webcast will be available on the investor relations website. Sight Sciences specializes in innovative eyecare solutions, focusing on minimally invasive treatments for glaucoma and other prevalent eye diseases.
Notable products include the OMNI® Surgical System for glaucoma management and the TearCare® System for dry eye disease.
Details
News Market Reaction – SGHT
The recorded move for SGHT in the trading session of this news was -0.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team
MENLO PARK, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will host a Surgical Glaucoma Investor Symposium in San Diego, CA on Friday, May 5, 2023 at 6:00 pm PT. The event will include presentations from leading OMNI® and SION™ surgeons and remarks from the Sight Sciences executive management team.
A live and archived webcast of the event will be available on Sight Science’s investor relations website at https://investors.sightsciences.com. Please note that Q&A will be conducted live, in-person only following the formal presentations.
In-person attendance at the event will be limited and require advanced registration. Please email philip@gilmartinir.com by April 21, 2023 to request an invitation.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences. SION is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.